July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Role of Central Insulin Resistance in Glaucoma
Author Affiliations & Notes
  • Muneeb Ahmad Faiq
    Department of Ophthalmology, New York University School of Medicine, New York, New York, United States
    Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Tanuj Dada
    Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Trina Sengupta
    Department of Physiology, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Madhu Nath
    Department of Ocular Pharmacology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Thirumurthy Velpandian
    Department of Ocular Pharmacology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Kevin Chan
    Department of Ophthalmology, New York University School of Medicine, New York, New York, United States
    Department of Radiology, New York University School of Medicine, New York, New York, United States
  • Footnotes
    Commercial Relationships   Muneeb Faiq, None; Tanuj Dada, None; Trina Sengupta, None; Madhu Nath, None; Thirumurthy Velpandian, None; Kevin Chan, None
  • Footnotes
    Support  This work was supported in part by the institutional funds from All India Institute of Medical Sciences (New Delhi, India); the National Institutes of Health R01-EY028125 (Bethesda, Maryland); BrightFocus Foundation G2013077 and G2016030 (Clarksburg, Maryland); and Research to Prevent Blindness/Stavros Niarchos Foundation International Research Collaborators Award (New York, New York).
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 682. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Muneeb Ahmad Faiq, Tanuj Dada, Trina Sengupta, Madhu Nath, Thirumurthy Velpandian, Kevin Chan; Role of Central Insulin Resistance in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2019;60(9):682.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Central insulin resistance (CIR) has been implicated in many neurodegenerative conditions. CIR was recently suggested to be a major risk factor for glaucoma also but this supposition lacks coherent scientific evidence. In order to examine this hypothesis, we used intracerebral injection of S961 (a potent blocker of insulin receptor; IR) in rodents to test if CIR lead to pathological changes akin to glaucoma.

Methods : A guide cannula (24 gauge, 15mm long) was stereotaxically implanted either in the left or right lateral ventricle in Wistar rats weighing 200g-250g through a burr hole 0.5 mm posterior to the coronal suture, 2mm lateral to the sagittal suture and 3mm below the dura mater according to the coordinates 5.4 mm A, 2mm L, 4mmV as per De Groot atlas. A post-surgical recovery period of 7 days was given to the animals before S961 (Group 1, n=6) or control buffer (Group 2, n=6) was injected. Intraocular pressure (IOP) measurements were taken with TonoPen XL over 24 days. Histology was done on the retina using H&E and crystal violet staining at Day-0, Day-14 and Day-24 post-S961 or buffer injection. Retinal insulin receptor expression was performed by immunohistochemistry (IHC), gene expression profile was done using real-time polymer chain reaction (PCR) and protein expression with western blotting.

Results : While no significant change in IOP in the control group was observed (13.4 ± 2.6 mmHg on Day-0 to 14.6±2.1 mmHg on Day-24; p=0.06), intracerebral injection of S961 led to an increase in IOP from 12.2±2 mmHg on Day-0 to 28.1±3.4 mmHg on Day-24 (p<0.05) with decrease in the cell density and IR expression in the retinal ganglion cell (RGC) layer. These changes were accompanied with upregulation of IL2, IL4, FGFR1, GSK3a, and GSK3b with fold change of 1.98, 2.78, 1.53, 1.6, 1.22 respectively and downregulation of IGF2, MAPK15, NFKB1A, PI3K, NRG1, BCL2L11, IGF1, RARB and IR with 2.35, 1.65, 2.39, 2.07, 2.05, 1.94, 1.55, 2.14, 3.3 fold changes respectively. Western blot showed elevation of TNF-α and GFAP in the retina after S961 injection.

Conclusions : These results indicate that blocking IR in the central nervous system is associated with elevation in IOP, loss of RGCs and changes in gene and protein expression relevant to RGC apoptosis. This study indicates that CIR may have an etiopathogenic role to play in glaucomatous neurodegeneration and targeting insulin signaling may hold promise as potential therapeutic modality for glaucoma.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×